The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study.

Taner CoşkunerŞengül ÇağlayanÖzlem AkgünRüya TorunEmine Nur Sunar YaylaI Lknur BagrulGülşah KılbaşGülçin Otar YenerHülya KöseKübra ÖztürkÖzge BabaMustafa ÇakanFerhat DemirHafize Emine SönmezMukaddes KalyoncuSara Nşebnem KılıçSelçuk YükselEsra BağlanSevcan A BakkaloğluErbil ÜnsalNuray Aktay AyazBetül Sözeri

Published in: Expert opinion on biological therapy (2023)

Real-lifedata from a large cohort of patients suggests that canakinumab is assafe as claimed in clinical trials.

Keyphrases

juvenile idiopathic arthritis
clinical trial
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
disease activity
randomized controlled trial
patient reported outcomes
systemic lupus erythematosus
open label